$930,000.00 in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter

Equities analysts expect AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to post sales of $930,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AcelRx Pharmaceuticals’ earnings, with estimates ranging from $550,000.00 to $1.30 million. AcelRx Pharmaceuticals posted sales of $2.66 million in the same quarter last year, which suggests a negative year-over-year growth rate of 65%. The company is scheduled to report its next quarterly earnings report on Tuesday, August 7th.

On average, analysts expect that AcelRx Pharmaceuticals will report full-year sales of $6.35 million for the current financial year, with estimates ranging from $1.99 million to $10.70 million. For the next financial year, analysts expect that the business will post sales of $23.07 million per share, with estimates ranging from $17.40 million to $28.74 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.78 million.

A number of research firms recently weighed in on ACRX. ValuEngine raised shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Cantor Fitzgerald began coverage on shares of AcelRx Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $6.00 target price for the company. Finally, Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Tuesday, May 15th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. AcelRx Pharmaceuticals has a consensus rating of “Buy” and an average price target of $5.11.

Several institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in shares of AcelRx Pharmaceuticals in the 1st quarter valued at about $113,000. Northern Trust Corp grew its position in shares of AcelRx Pharmaceuticals by 60.8% in the 1st quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after acquiring an additional 34,584 shares during the period. Geller Family Office Services LLC grew its position in shares of AcelRx Pharmaceuticals by 175.0% in the 4th quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock valued at $557,000 after acquiring an additional 175,000 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of AcelRx Pharmaceuticals in the 4th quarter valued at about $120,000. 8.40% of the stock is owned by institutional investors.

AcelRx Pharmaceuticals stock traded up $0.23 during mid-day trading on Monday, reaching $4.13. The company’s stock had a trading volume of 994,112 shares, compared to its average volume of 503,621. The company has a market cap of $187.32 million, a P/E ratio of -3.75 and a beta of 2.36. AcelRx Pharmaceuticals has a 12 month low of $1.55 and a 12 month high of $5.75. The company has a current ratio of 4.05, a quick ratio of 4.00 and a debt-to-equity ratio of -0.20.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply